SEC Filing Summary: Galena Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on April 7, 2016, reporting an event that occurred on April 6, 2016. The filing addresses the company's compliance status with the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
The primary material change reported is the resolution of a listing deficiency. Galena Biopharma received notice from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1). This compliance was achieved because the bid price of the Company's common stock closed at or above $1.00 per share for ten consecutive trading days prior to the notice date.
Guidance, Outlook, and Risks
The filing indicates that the matter regarding the listing deficiency is now closed. No financial guidance, management commentary on future operations, or new risk factors are disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of Galena Biopharma common stock to ensure it remains above the $1.00 threshold.
- Confirm the company's continued compliance with other Nasdaq listing requirements beyond Rule 5450(a)(1).
- Note that the company name in the metadata (SELLAS Life Sciences Group, Inc.) differs from the registrant in the filing (Galena Biopharma, Inc.); verify the correct entity for investment purposes.